Study Objectives: Insomnia is a common sleep disorder that is associated with a range of adverse outcomes. Patients with insomnia exhibit hyperarousal in multiple domains, including an elevated metabolic rate, but specific metabolic molecular perturbations are unknown. Furthermore, objective clinical markers of insomnia are not available and current assessment of pathological extent relies on self-report. Here, we provide preliminary evidence that chronic insomnia is remarkably reflected in the periphery through detailed metabolic assessments. Methods: Serum from confirmed patients with insomnia and matched good sleepers (n = 15 per group) was sampled at high temporal resolution (every 2 hr over 48 hr). Food intake was controlled by providing hourly isocaloric snacks, and sleep architecture was assessed by overnight polysomnography. Quantitative metabolic assessments were conducted using nuclear magnetic resonance spectroscopy. Results: Global metabolic profiles differentiated patients with insomnia from healthy controls, with elevated amino acid and energy metabolites and reduced branched-chain amino acid catabolic products. Strikingly, branched-chain amino acid catabolism was found to be specifically altered during the night with ~10 per cent increased accumulation of glucose in insomnia patients. Rhythmicity analysis revealed 11 metabolites that cycled diurnally across both groups, with phase advances noted for acetone and delays for lactate and branched-chain amino acids and their products. Conclusions: These preliminary observations suggest that insomnia is associated with quantitative metabolic dysregulation and supports the hyperarousal hypothesis. Furthermore, we posit that these changes lead to a state of metabolic desynchrony in insomnia that is involved in the pathophysiology of the disorder and/or mediates its impact on health outcomes. Clinical Trials Registration: NCT01957111.
Study Objectives:Insomnia is a common sleep disorder that is associated with a range of adverse outcomes. Patients with insomnia exhibit hyperarousal in multiple domains, including an elevated metabolic rate, but specific metabolic molecular perturbations are unknown. Furthermore, objective clinical markers of insomnia are not available and current assessment of pathological extent relies on self-report. Here, we provide preliminary evidence that chronic insomnia is remarkably reflected in the periphery through detailed metabolic assessments. Methods: Serum from confirmed patients with insomnia and matched good sleepers (n = 15 per group) was sampled at high temporal resolution (every 2 hr over 48 hr). Food intake was controlled by providing hourly isocaloric snacks, and sleep architecture was assessed by overnight polysomnography. Quantitative metabolic assessments were conducted using nuclear magnetic resonance spectroscopy. Results: Global metabolic profiles differentiated patients with insomnia from healthy controls, with elevated amino acid and energy metabolites and reduced branched-chain amino acid catabolic products. Strikingly, branched-chain amino acid catabolism was found to be specifically altered during the night with ~10 per cent increased accumulation of glucose in insomniapatients. Rhythmicity analysis revealed 11 metabolites that cycled diurnally across both groups, with phase advances noted for acetone and delays for lactate and branched-chain amino acids and their products. Conclusions: These preliminary observations suggest that insomnia is associated with quantitative metabolic dysregulation and supports the hyperarousal hypothesis. Furthermore, we posit that these changes lead to a state of metabolic desynchrony in insomnia that is involved in the pathophysiology of the disorder and/or mediates its impact on health outcomes. Clinical Trials Registration: NCT01957111.
Authors: Rosa van den Berg; Dennis O Mook-Kanamori; Esther Donga; Marieke van Dijk; J Gert van Dijk; Gert-Jan Lammers; Klaas W van Kralingen; Cornelia Prehn; Jerzy Adamski; Johannes A Romijn; Ko Willems van Dijk; Eleonora P M Corssmit; Patrick C N Rensen; Nienke R Biermasz Journal: Arch Biochem Biophys Date: 2015-09-21 Impact factor: 4.013
Authors: Michael R Irwin; Richard Olmstead; Elizabeth C Breen; Tuff Witarama; Carmen Carrillo; Nina Sadeghi; Jesusa M G Arevalo; Jeffrey Ma; Perry Nicassio; Patricia A Ganz; Julienne E Bower; Steve Cole Journal: J Natl Cancer Inst Monogr Date: 2014-11
Authors: Jack D Edinger; James K Wyatt; Edward J Stepanski; Maren K Olsen; Karen M Stechuchak; Colleen E Carney; Ambrose Chiang; M Isabel Crisostomo; Margaret D Lineberger; Melanie K Means; Rodney A Radtke; William K Wohlgemuth; Andrew D Krystal Journal: Arch Gen Psychiatry Date: 2011-06-06
Authors: Thomas Roth; Catherine Coulouvrat; Goeran Hajak; Matthew D Lakoma; Nancy A Sampson; Victoria Shahly; Alicia C Shillington; Judith J Stephenson; James K Walsh; Ronald C Kessler Journal: Biol Psychiatry Date: 2010-12-31 Impact factor: 13.382
Authors: Eric Chern-Pin Chua; Guanghou Shui; Ivan Tian-Guang Lee; Pauline Lau; Luuan-Chin Tan; Sing-Chen Yeo; Buu Duyen Lam; Sarada Bulchand; Scott A Summers; Kathiravelu Puvanendran; Steven G Rozen; Markus R Wenk; Joshua J Gooley Journal: Proc Natl Acad Sci U S A Date: 2013-08-14 Impact factor: 11.205
Authors: Chiara Lasconi; Matthew C Pahl; James A Pippin; Chun Su; Matthew E Johnson; Alessandra Chesi; Keith Boehm; Elisabetta Manduchi; Kristy Ou; Maria L Golson; Andrew D Wells; Klaus H Kaestner; Struan F A Grant Journal: Sleep Date: 2022-08-11 Impact factor: 6.313
Authors: Jennifer R Goldschmied; Arjun Sengupta; Anup Sharma; Lynne Taylor; Knashawn H Morales; Michael E Thase; Michael E Thase; Aalim Weljie; Matthew S Kayser Journal: Psychopharmacol Bull Date: 2021-06-01
Authors: Julia L Chapman; Maria Comas; Camilla M Hoyos; Delwyn J Bartlett; Ronald R Grunstein; Christopher J Gordon Journal: Front Endocrinol (Lausanne) Date: 2018-07-16 Impact factor: 5.555
Authors: Guanying Wang; Xiaojuan Ren; Xingping Zhang; Qingquan Wang; Tao Liu; Ning Deng; Deqi Yan Journal: Biomed Res Int Date: 2021-01-13 Impact factor: 3.411